Back

Phenotypic manifestation based on genetics and prevalence of secondary mutations in a sample of patients diagnosed with arrhythmogenic cardiomyopathy

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Markers in and of dilated cardiomyopathy Dilated Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Arancha Diaz Exposito

Virgin of Victory University Hospital, Malaga (Spain)

5 More presentations in this session

Presentation thumbnail
Influence of non-sex specific risk factors on the development of a dilated cardiomyopathy in men and women with a titin truncating variant
Ms I. Faassen (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Genetic determinants of disease severity in idiopathic dilated cardiomyopathy
Associate Professor J. Lee (Cheongju, KR)
Abstract Slides Video
Presentation thumbnail
Relationship between TTN gene mutation and changes in whole-heart myocardial mechanics in patients with non-ischemic dilated cardiomyopathy: feature-tracking CMR study
Ms G. Jakuskaite (Kaunas, LT)
Abstract Slides Video
Presentation thumbnail
Is left ventricular ejection fraction an effective predictor of ventricular arrhythmias in patients with dilated cardiomyopathy?
Doctor M. Rodrigues Simoes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Biomarkers in action: The role of Procalcitonin, NT-proBNP, and Troponin T in predicting septic cardiomyopathy
Doctor D. Ferreira (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Markers in and of dilated cardiomyopathy

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
The impact of desmosomal mutations on clinical features in arrhythmogenic cardiomyopathy: towards tailored arrhythmic risk stratification
thumbnail
Congress Presentation
Incidence and progression of left ventricular involvement in patients with arrythmogenic cardiomyopathy
thumbnail
Congress Presentation
Prevalence of ICD therapies in primary prevention vs secondary prevention in a sample of patients diagnosed with arrhythmogenic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources